European regulators said on Thursday they have completed their assessment of drug manufacturing violations at Ranbaxy Laboratories Ltd's facility in Toansa, India, and although deficiencies were found, they pose no risk to public health. The regulators said they were satisfied by corrective measures put in place by the company after U.S. regulators found deviations in January. The assessment stands in stark contrast to the response of U.S. regulators to the deficiencies found at the plant.